230 related articles for article (PubMed ID: 9140134)
1. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders.
Gassen M; Youdim MB
Pharmacol Toxicol; 1997 Apr; 80(4):159-66. PubMed ID: 9140134
[TBL] [Abstract][Full Text] [Related]
2. Iron and Parkinson's disease: chelators to the rescue?
Levenson CW
Nutr Rev; 2003 Sep; 61(9):311-3. PubMed ID: 14552066
[TBL] [Abstract][Full Text] [Related]
3. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28.
Youdim MB; Stephenson G; Ben Shachar D
Ann N Y Acad Sci; 2004 Mar; 1012():306-25. PubMed ID: 15105275
[TBL] [Abstract][Full Text] [Related]
4. A review on iron chelators as potential therapeutic agents for the treatment of Alzheimer's and Parkinson's diseases.
Singh YP; Pandey A; Vishwakarma S; Modi G
Mol Divers; 2019 May; 23(2):509-526. PubMed ID: 30293116
[TBL] [Abstract][Full Text] [Related]
5. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
Youdim MB; Fridkin M; Zheng H
J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
[TBL] [Abstract][Full Text] [Related]
6. Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators.
Weinreb O; Mandel S; Youdim MBH; Amit T
Free Radic Biol Med; 2013 Sep; 62():52-64. PubMed ID: 23376471
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's disease.
Edwin Shackelford R; Manuszak RP; Heard SC; Link CJ; Wang S
Med Hypotheses; 2005; 64(4):736-41. PubMed ID: 15694690
[TBL] [Abstract][Full Text] [Related]
8. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
Mandel S; Maor G; Youdim MB
J Mol Neurosci; 2004; 24(3):401-16. PubMed ID: 15655262
[TBL] [Abstract][Full Text] [Related]
9. Neurodegenerative diseases and therapeutic strategies using iron chelators.
Ward RJ; Dexter DT; Crichton RR
J Trace Elem Med Biol; 2015; 31():267-73. PubMed ID: 25716300
[TBL] [Abstract][Full Text] [Related]
10. Oxidative stress and neurodegeneration: the involvement of iron.
Carocci A; Catalano A; Sinicropi MS; Genchi G
Biometals; 2018 Oct; 31(5):715-735. PubMed ID: 30014355
[TBL] [Abstract][Full Text] [Related]
11. Ironing out Parkinson's disease: is therapeutic treatment with iron chelators a real possibility?
Kaur D; Andersen JK
Aging Cell; 2002 Oct; 1(1):17-21. PubMed ID: 12882349
[TBL] [Abstract][Full Text] [Related]
12. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
Zheng H; Gal S; Weiner LM; Bar-Am O; Warshawsky A; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):68-78. PubMed ID: 16181413
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.
Zheng H; Weiner LM; Bar-Am O; Epsztejn S; Cabantchik ZI; Warshawsky A; Youdim MB; Fridkin M
Bioorg Med Chem; 2005 Feb; 13(3):773-83. PubMed ID: 15653345
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress in Parkinson's disease and other neurodegenerative disorders.
Jenner P
Pathol Biol (Paris); 1996 Jan; 44(1):57-64. PubMed ID: 8734302
[TBL] [Abstract][Full Text] [Related]
15. Iron in neurodegenerative disorders: being in the wrong place at the wrong time?
Apostolakis S; Kypraiou AM
Rev Neurosci; 2017 Nov; 28(8):893-911. PubMed ID: 28792913
[TBL] [Abstract][Full Text] [Related]
16. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease.
Jellinger KA
Drugs Aging; 1999 Feb; 14(2):115-40. PubMed ID: 10084365
[TBL] [Abstract][Full Text] [Related]
17. Iron and Parkinson's disease.
Di Lorenzo F
Neuro Endocrinol Lett; 2015; 36(1):24-7. PubMed ID: 25789591
[TBL] [Abstract][Full Text] [Related]
18. Striking while the iron is hot: Iron metabolism and ferroptosis in neurodegeneration.
Masaldan S; Bush AI; Devos D; Rolland AS; Moreau C
Free Radic Biol Med; 2019 Mar; 133():221-233. PubMed ID: 30266679
[TBL] [Abstract][Full Text] [Related]
19. Free-radical toxicity and antioxidant medications in Parkinson's disease.
Ciccone CD
Phys Ther; 1998 Mar; 78(3):313-9. PubMed ID: 9520976
[No Abstract] [Full Text] [Related]
20. An introduction to the free radical hypothesis in Parkinson's disease.
Olanow CW
Ann Neurol; 1992; 32 Suppl():S2-9. PubMed ID: 1510376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
